Cargando…
Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors
[Image: see text] Targeting the protein–protein interaction between p53 and MDM2/MDMX (MDM4) represents an attractive anticancer strategy for the treatment of p53-competent tumors. Several selective and potent MDM2 inhibitors have been developed and entered the clinic; however, the repertoire of MDM...
Autores principales: | Stefaniak, Jakub, Lewis, Andrew M., Conole, Daniel, Galan, Sébastien R. G., Bataille, Carole J. R., Wynne, Graham M., Castaldi, M. Paola, Lundbäck, Thomas, Russell, Angela J., Huber, Kilian V. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198280/ https://www.ncbi.nlm.nih.gov/pubmed/30216042 http://dx.doi.org/10.1021/acschembio.8b00665 |
Ejemplares similares
-
Mdmx promotes genomic instability independent of p53 and Mdm2
por: Carrillo, Alexia M., et al.
Publicado: (2014) -
Is MDMX the better target?
por: Kon, Ning, et al.
Publicado: (2018) -
Role of Mdm2 and Mdmx in DNA repair
por: Eischen, Christine M.
Publicado: (2017) -
Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019) -
MDMX elevation by a novel Mdmx–p53 interaction inhibitor mitigates neuronal damage after ischemic stroke
por: Yan, Haomin, et al.
Publicado: (2022)